Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.

TitleReciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.
Publication TypeJournal Article
Year of Publication2003
AuthorsJĂșnior GMoreira, Colleoni GWB, M Cangi G, Murphy M, Sherburne B, Bordin JO, Loda M
JournalDiagn Mol Pathol
Volume12
Issue3
Pagination128-32
Date Published2003 Sep
ISSN1052-9551
Keywordscdc25 Phosphatases, Cell Count, Female, Gene Expression Regulation, Neoplastic, Humans, Immunoenzyme Techniques, In Situ Hybridization, Lymphoma, B-Cell, Microfilament Proteins, Muscle Proteins, Retrospective Studies, RNA, Messenger, RNA, Neoplasm
Abstract

Cell cycle regulation is often altered in cancer and deregulation of the cell cycle checkpoints is common in human neoplasia. The dual-specificity phosphatase Cdc25A and the cell cycle inhibitor p27 both play an important role in the regulation of the G1-S transition. We evaluated Cdc25A mRNA expression by in situ hybridization and p27 protein expression by immunohistochemistry in 42 histologically indolent B-cell non-Hodgkin lymphoma (NHL and 51 histologically aggressive B-cell NHL. Overexpression of Cdc25A (>50% tumor cells positive) was detected in 5 of 42 cases (12%) of histologically indolent B-cell NHL and in 29 of 51 (57%) of histologically aggressive B-cell NHL (P < 0.001). In contrast, high p27 protein expression (>50% tumor cells positive) was observed in 29 (69%) cases of indolent but in only one case (2%) of aggressive B-cell NHL (P < 0.0001). Thus, overexpression of Cdc25A and concomitant loss of p27 expression are associated with high grade B-cell NHL and may contribute to their aggressive biologic behavior.

DOI10.1097/00019606-200309000-00003
Alternate JournalDiagn Mol Pathol
PubMed ID12960694
Grant ListR01-CA81755 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700